Umeclidinium Bromide; Indications, Dosage, Side Effects, Interaction, Pregnancy

Umeclidinium Bromide; Indications, Dosage, Side Effects, Interaction, Pregnancy

Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). It is available as a once-daily inhalation monotherapy or as a fixed-dose combination product with the long-acting beta2-agonist vilanterol. COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%. By blocking the M3 muscarinic receptor which is highly expressed in airway smooth muscle of the lungs, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction. Its use has been shown to provide clinically significant, sustained improvements in lung function.

Umeclidinium bromide is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also approved for this indication in combination with vilanterol

Mechanism of Action of Umeclidinium Bromide

Umeclidinium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through the inhibition of the M3 receptor at the smooth muscle leading to bronchodilation.

Indications of Umeclidinium Bromide

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Bronchiectasis
  • Bronchospasm Prophylaxis
  • Bronchial asthma,
  • Chronic bronchitis,
  • Chronic bronchopulmonary disorders
  • Airflow obstruction in patients with chronic obstructive pulmonary disease (COPD),
  • Chronic bronchitis and/or emphysema.
  • Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
  • Incruse is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
  • Rolufta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Contra-Indications of Umeclidinium Bromide

You Might Also Like   Uses Indications of Botox Injections, Pregnancy Category

The dosage of Umeclidinium Bromide

Strengths: 62.5 mcg (0.0625 mg)/inh

Chronic Obstructive Pulmonary Disease – Maintenance

  • 1 inhalation (62.5 mcg) orally once a day
  • Maximum dose: 1 inhalation every 24 hours

Side Effects

The most common

More common

Rare

You Might Also Like   Are You Worried About Knee Joints Pain? Regenerative Medicine

Drug Interactions

Umeclidinium bromide  may interact with the following drugs, supplements & may change the efficacy of drugs

Pregnancy Catagory

FDA Pregnancy Category C

Pregnancy

In animal studies, pregnant animals were given this medication and there was no evidence of problems for the mother or offspring. No well-controlled studies have been done in humans. Therefore, this medication may be used if the potential benefits to the mother outweigh the potential risks to the unborn child.

Lactation

It is not known if umeclidinium crosses into human milk. Because many medications can cross into human milk and because of the possibility for serious adverse reactions in nursing infants with use of this medication, a choice should be made whether to stop nursing or stop the use of this medication.

References

  1. https://pubchem.ncbi.nlm.nih.gov

 

Umeclidinium

About the author

Translate »